See how Apple Inc. and Eli Lilly and Company differ across market data and performance, so you can decide which asset best fits your strategy.
$333.74
NasdaqGS
Apple Inc. is one of the world’s largest companies, offering a broad portfolio of hardware and software products for both consumers and businesses. The iPhone accounts for the majority of Apple’s revenue, while products such as the Mac, iPad, and Apple Watch are built around the iPhone as the centerpiece of a wide-reaching software ecosystem. Over time, Apple has expanded its offerings with new services and applications, including streaming video, subscription bundles, and augmented reality. The company designs its own software and semiconductors, while relying on manufacturing partners such as Foxconn and TSMC to produce its devices and chips. Slightly less than half of Apple’s sales are generated through its flagship retail stores, with most revenue coming indirectly through partnerships and distribution channels.
Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.